Accessibility: Skip TopNav
Overall Survival (n=28, median follow-up 4.3 months)
As of Jan 6, 2019; evaluable patients include patients completing one cycle of therapy
Format
JPEG
Source
Tyme Technologies, Inc.
Downloads
Original
Large
Medium
Small